NCT05164016
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Drug Category: Other
Key Eligibility Criteria:
Gender: All
Age: up to 24 Years (Child, Adult))
Location of Metastases:
Additional Notes:
Exclusions: Patients older than 24 years of age
https://ClinicalTrials.gov/show/NCT05164016